Sezary syndrome

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This phase 2 trial tests a drug called PTX-100 in 115 adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants receive PTX-100 by IV infusion over several cycles. The goal is to see if the drug can shrink or eliminate tumors an…

This phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advan…

This early-stage trial is testing an experimental drug called KK2223 in 72 adults with T-cell lymphoma (a type of blood cancer) that has returned or not responded to prior treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processe…

This study tests two drugs—durvalumab (an immunotherapy) and lenalidomide (a chemotherapy drug)—alone or together in people with T-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the best dose and see how well the combination works. About …

This trial tests whether combining the drug mogamulizumab with low-dose total skin electron beam therapy works better than either alone for people with mycosis fungoides or Sezary syndrome, two rare types of skin lymphoma. Participants receive both treatments over several weeks. …

This study tests whether combining two drugs, pembrolizumab and mogamulizumab, can shrink or control advanced cutaneous T-cell lymphoma (a type of skin cancer) that has returned or not responded to prior therapy. About 23 adults with stage IIB to IVB disease will receive the drug…

This study is testing whether a lower dose of the drug brentuximab vedotin can still effectively treat three types of skin lymphoma: mycosis fungoides, Sezary syndrome, and lymphomatoid papulosis. The goal is to see if reducing the dose can maintain benefits while possibly loweri…

This early-phase trial tests an investigational drug called ropeginterferon in 38 adults with cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Participants must have tried at least two prior treatments without success. The main goals are to find the safest dose and s…

This study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…

This phase 2 trial is testing whether a procedure called extracorporeal photopheresis (ECP) can reduce tumor cells in people with Sezary syndrome, a rare blood cancer that affects the skin. Twenty participants will receive ECP weekly for a month, then every two weeks for five mon…

This early-stage trial is testing a new form of fenretinide (a vitamin A-like drug) given by IV for people with T-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose in small groups of patients, …

This study is tracking how safe and effective the drug mogamulizumab (Poteligeo) is for adults with two rare types of skin lymphoma: mycosis fungoides and Sézary syndrome. Researchers will monitor 15 participants in routine care settings for side effects and how well the drug con…

This study tracks 100 adults with mycosis fungoides or Sézary syndrome who are starting mogamulizumab, a standard treatment. The drug often causes a rash that can look like the cancer itself. Researchers want to help doctors tell the difference so they don't stop a working drug t…

This study looks at blood and skin samples from people with mycosis fungoides and Sézary syndrome, rare types of lymphoma that affect the skin. Researchers want to find biological markers that can predict how the disease will progress and how well a patient might respond to treat…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…

This study collects blood, urine, and skin samples from 200 adults with cutaneous T-cell lymphoma, eczema, or atopic dermatitis. The samples are stored and used for current and future research, such as studying proteins in the blood and tissue. Participants must have one of these…

This study looks back at medical records of 400 adults with cutaneous T-cell lymphoma (CTCL) to see which systemic therapies doctors actually use and in what order. It aims to describe real-world treatment patterns, not test a new drug. The results may help guide future treatment…

This study collects and stores tissue samples from people with cutaneous T-cell lymphoma (CTCL) and healthy volunteers. Researchers will use these samples to study how T cells change in CTCL. No treatment is given—the goal is to gather information for future research. Up to 400 p…

This study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…

This study is collecting medical information from 2000 people with advanced mycosis fungoides or Sézary syndrome, two rare types of skin lymphoma. The goal is to create a tool that helps doctors predict which patients are at higher or lower risk, so they can tailor treatments mor…